BML-210
Product Specifications
UNSPSC Description
BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice[1][2][3].
Target Antigen
Apoptosis; HDAC
Type
Reference compound
Related Pathways
Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BML-210.html
Purity
98.06
Solubility
DMSO : ≥ 30 mg/mL
Smiles
O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
Molecular Weight
339.43
References & Citations
[1]Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40(12): 5378–5388.|[2]Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16(8): 18252–18269.|[3]Zhuolong Zhou, et al. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng. 2021 Nov;5(11):1320-1335.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-19350/BML-210-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-19350/BML-210-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
537034-17-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
